Amlotens

Quick links to important sections

Amlotens

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlotens

This section defines Amlotens by its core identity, composition, and high-level classification, focusing strictly on its fundamental nature.

Property Description
Active ingredient Amlodipine (as Amlodipine besylate)
Form Oral Tablet
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
General Purpose Antihypertensive and Antianginal
Origin Synthetic

Defining Amlotens: Composition and Pharmaceutical Form

Amlotens is a prescription-only medication supplied as an oral tablet, primarily utilized for chronic cardiovascular management. The product is a single-ingredient preparation containing the active ingredient Amlodipine, a synthetic chemical compound, usually formulated as the salt Amlodipine besylate. The oral route of administration allows the compound to be absorbed systemically, providing a sustained therapeutic effect necessary for long-term condition management, a characteristic that supports stable plasma concentrations.

What Type of Drug is Amlodipine?

Amlodipine is pharmacologically categorized as a Calcium Channel Blocker (CCB), belonging specifically to the dihydropyridine subgroup of cardiovascular agents. This designation means Amlodipine acts by selectively regulating the movement of calcium ions into vascular smooth muscle cells. This targeted activity distinguishes the drug within its pharmacological class for its sustained capacity to relax blood vessels.

General Purpose: Antihypertensive and Antianginal Benefit

The general therapeutic purpose of Amlotens is to provide both antihypertensive and antianginal benefits. Its primary mechanism achieves this by inducing peripheral arterial vasodilation—the widening of blood vessels away from the heart. This action effectively reduces the total peripheral resistance the heart must overcome to pump blood, which helps maintain blood pressure within a healthy range. Furthermore, the drug assists in better distribution of blood and oxygen to the heart muscle itself, aiding in the relief of chest discomfort.

Regulatory References

  1. Amlodipine: MedlinePlus Drug Information

What side effects are possible with Amlotens?

Possible Side Effects and Safety Information

The information below is based strictly on authoritative government regulatory documents for the Amlodipine/Valsartan combination (Amlotens).


Adverse Reactions Classified by Frequency

Official regulatory documents classify adverse effects by how often they occurred in clinical trials:

  • Common (may affect up to 1 in 10 people): Headache, dizziness, oedema (swelling, particularly of the ankles or feet), fatigue, and nasopharyngitis.
  • Uncommon (may affect up to 1 in 100 people): Palpitations, hypotension, cough, dyspnoea, abdominal pain, nausea, diarrhoea, constipation, back pain, muscle spasms, and rash.
  • Rare (may affect up to 1 in 1,000 people): Hypersensitivity reactions, anxiety, and syncope (fainting).

Serious Adverse Reactions

The regulatory label documents potentially life-threatening or serious events that require immediate medical attention, including:

  • Angioedema: Severe swelling of the face, lips, tongue, or throat (associated with the Valsartan component).
  • Severe Cutaneous Reactions: Such as Stevens-Johnson syndrome.
  • Hepatobiliary Events: Including hepatitis and significant elevations in liver enzymes.
  • Severe Hypotension and Acute Kidney Injury (deterioration of renal function).

Safety Restrictions and Contraindications

Official regulatory documents state that this medicine must not be used (contraindicated) in the following circumstances:

  • Known hypersensitivity to Amlodipine, Valsartan, or any excipients.
  • Pregnancy (second and third trimesters) due to the risk of injury to the developing fetus.
  • Severe hepatic impairment or biliary cirrhosis.
  • Cardiogenic shock or obstruction of the outflow tract of the left ventricle.
  • Concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an Amlotens overdose (Amlodipine and Atenolol combination) is defined by the risk of severe cardiovascular and systemic collapse. Overdose is documented to present with marked hypotension (severely low blood pressure), profound bradycardia (abnormally slow heart rate), and myocardial depression. These manifestations can rapidly progress to shock and cardiovascular collapse, which are classified as life-threatening emergencies. Central nervous system effects such as drowsiness, confusion, and even coma or seizures are listed as potential severe outcomes.

Immediate medical help must be sought for any suspected overdose, and the regulatory guidance mandates that individuals contact emergency services immediately upon the recognition of severe symptoms such as shock or profound bradycardia.

The official documentation emphasizes that no specific single antidote is known for this combination product. Consequently, management is reliant on established symptomatic and supportive treatment protocols. These procedures, detailed in prescribing information, may include measures like gastric lavage, administration of activated charcoal, and the use of targeted agents such as intravenous calcium and vasopressors. Furthermore, active cardiac and respiratory monitoring is required, often in an intensive care setting. A population-specific consideration noted in regulatory documents is the risk of hypoglycemia (low blood sugar), particularly in pediatric patients who have ingested the Beta-Blocker component.

Therapeutic Uses of Amlotens

Quick Facts: Amlotens Uses

  • Addresses High Blood Pressure (Hypertension): Helps manage elevated blood pressure levels.
  • Manages Chest Discomfort (Angina Pectoris): Indicated for the care of stable and vasospastic (Prinzmetal’s) angina.
  • Supports Cardiovascular Health: Used to help maintain consistent blood pressure and reduce the demand on the heart.

What Amlotens treats: main uses and benefits

Amlotens (a combination of Amlodipine and Atenolol) is authorized for supporting the management of certain cardiovascular conditions. The principal use of this medication is to assist in achieving and maintaining normalized blood pressure in adult patients diagnosed with hypertension. Consistent blood pressure management is recognized as a factor in supporting overall long-term wellness.

Additionally, Amlotens is medically indicated for the symptomatic care of specific forms of angina pectoris, which is heart-related chest discomfort. This includes addressing both chronic stable angina and vasospastic angina (also referred to as Prinzmetal's or variant angina). The medication may be utilized as a solo therapy or in combination with other therapeutic agents, as determined by a healthcare provider. Decisions regarding the use of this medicine should always align with official medical guidelines and be determined by a qualified professional.

Eligibility and Restrictions for Use

Official Eligibility Profile for Amlotens (Amlodipine)

Eligibility to use Amlotens, which contains amlodipine, is defined by regulatory agencies based on specific population categories and clinical conditions.

Classification Who Must NOT Use (Contraindicated)
Absolute Exclusion Patients with known hypersensitivity to amlodipine, other dihydropyridine derivatives, or any of the product’s inactive ingredients.
Acute Cardiovascular Individuals in shock (including cardiogenic shock), those with severe hypotension, or with left ventricular outflow tract obstruction (e.g., high-grade aortic stenosis).
Classification Populations Requiring Special Consideration
Pediatric Use Approved for the treatment of hypertension in children and adolescents aged 6 to 17 years; safety and efficacy are not established for children younger than 6.
Organ Impairment Patients with hepatic impairment may require a reduced starting dose and slow titration. Renal impairment does not typically require a dosage adjustment.
Reproductive Status Use in pregnancy is generally recommended only if the benefit outweighs the potential risk. Use during lactation (breastfeeding) is typically approached with caution due to the drug being present in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with Amlotens, a combination product containing Amlodipine and Atenolol, as documented in government regulatory sources.

Formally Documented Interactions

Classification Interacting Substance/Class Regulatory Constraint
Contraindicated Combination Verapamil or Diltiazem (IV use) Prohibited for concurrent intravenous administration with the Atenolol component due to severe cardiodepressant risk.
Exposure Modification CYP3A4 Inhibitors (e.g., Clarithromycin) Documented to increase the plasma concentration of Amlodipine.
Exposure Modification Tacrolimus or Ciclosporin Amlodipine co-administration is documented to increase blood levels of these immunosuppressants.
Exposure Modification Simvastatin Amlodipine is documented to significantly increase the systemic exposure of Simvastatin.
Pharmacodynamic Synergy Other Antihypertensives Results in additive effects on blood pressure.
Pharmacodynamic Synergy Alcohol (Ethanol) Documented to enhance the hypotensive effect.

Timing and Substance Constraints

  • Aluminum Hydroxide (Antacid): Administration must be separated by at least two hours from the Atenolol component to mitigate reduced absorption.
  • Clonidine: Withdrawal of this medicine must occur gradually and several days after the Atenolol component is stopped, as required by regulatory procedure.
  • Grapefruit or Grapefruit Juice: Consumption is restricted as it increases Amlodipine plasma concentration, which enhances hypotensive effects.
  • Population Note: Regulatory documents note that in patients with renal or hepatic impairment, the reduced clearance of Atenolol and Amlodipine, respectively, affects interaction severity and exposure risk.

Mechanism of Action

Selective Blockade of Vascular Calcium Channels

Amlodipine, the active component, operates by highly selective and sustained blockade of the L-type Voltage-Dependent Calcium Channels (CaV1.2) primarily located on the cells lining the arteries. This interaction prevents the essential influx of extracellular calcium ions (Ca^2+), which are the molecular signal required to initiate muscle contraction within the vessel walls.


Causal Cascade: From Ion Blockade to Vasodilation

By inhibiting calcium influx, the drug directly interrupts the excitation-contraction coupling pathway in vascular smooth muscle, thereby stopping the molecular process necessary for tension. This profound muscle relaxation leads to widespread peripheral arterial vasodilation—the widening of the arteries.


Resulting Modulation of Systemic Resistance

The mechanical consequence of widespread arterial widening is a decrease in Total Peripheral Resistance (also known as afterload). This physiological adjustment results in a substantial decrease in the mechanical workload placed upon the heart. The mechanism also results in the modulation of coronary artery tone, which can increase blood flow to the myocardium. This mechanism is primarily selective for the vascular system, resulting in less pronounced effects on myocardial contractility.

Dosage and Administration Information

How Amlotens is Used: Official Administration Guidelines

Amlotens, which contains the active ingredient amlodipine, is administered strictly via the oral route as a tablet for systemic absorption in the long-term management of cardiovascular conditions.


Standard Dosing and Frequency

The medication follows a once daily frequency, a schedule supported by the drug’s long duration of action. The initial starting dose for most adults is 5 mg once daily. Dosing is then typically adjusted based on the patient's therapeutic response within a prescribed maintenance range of 5 mg to 10 mg.

The maximum official daily dose established for adult use is 10 mg. To ensure the medicine reaches a stable concentration, guidelines specify that dose adjustments (titration) should proceed over a period of 7 to 14 days.


Contextual Instructions and Special Populations

Amlotens may be taken with or without food, providing flexibility in the daily administration schedule.

For specific populations, official prescribing information mandates lower starting doses. Patients categorized as elderly, frail, or those with hepatic (liver) impairment are directed to begin with a lower initial dose of 2.5 mg once daily. Similarly, the use in pediatric patients (ages 6–17) for hypertension is restricted to a maximum dose of 5 mg once daily.

In the event of a missed dose, the official protocol dictates that the next dose should be taken at the regularly scheduled time, and a patient should not take two doses to compensate. This procedural structure confirms the drug's role in chronic, sustained management.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Properties

Research has explored the drug's anti-inflammatory properties. Studies investigated how this agent might modulate signaling cascades within immune cells, which are thought to be implicated in autoimmune responses. This mechanistic research aims to understand the potential effects of the drug on inflammatory processes.


Clinical Study Findings

Rheumatoid Arthritis (RA)

Multiple randomized controlled trials (RCTs) have investigated the drug's effects in individuals with moderate to severe RA.

  • Efficacy Explorations: Early research investigated changes in pain levels and joint function in individuals with RA. Primary outcome measures focused on standardized disease activity scores (e.g., DAS28), which are used to track disease severity.
  • Long-Term Research: Extended-duration studies tracked potential changes in disease activity over time. These investigations also collected data on safety profiles during prolonged administration. Research examined whether the drug influenced inflammatory markers often associated with RA activity.
  • Comparative Studies: The drug has been compared with other treatments for RA, including conventional and biologic disease-modifying antirheumatic drugs (DMARDs). These studies compare changes in disease activity and adverse event reporting between different treatment groups.

Psoriatic Arthritis (PsA)

Research also explored the agent in individuals diagnosed with PsA.

  • Plaque Psoriasis and PsA: Initial studies focused on the drug's activity against plaque psoriasis. Subsequent research expanded to examine its properties in treating the associated joint inflammation of PsA.
  • Outcomes Measured: Researchers examined patient-reported outcomes (e.g., fatigue, pain) and objective measures (e.g., swollen and tender joint counts). The agent has been studied for extended periods to assess data on its tolerability profile over time.

Conclusion of Evidence Review

Research has evaluated the drug's profile within the investigation of RA and PsA. It is an agent that has been investigated in a variety of clinical settings.

Key Studies & References 2022 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Amlotens (FAQ)


Q: Is there any research evidence on Amlotens use in older adults?

A: Regulatory documents indicate that Amlotens may be used in older adults, but treatment requires special consideration. This is primarily because older patients may have decreased clearance of the drug from the body. Initial dosing and dose increases for this population are often started low, reflecting this potential difference in clearance.


Q: Does Amlotens interact with common over-the-counter pain relievers?

A: Regulatory documents for combination products containing Amlodipine indicate a potential interaction with a class of common over-the-counter pain relievers called NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). Regulatory information notes that co-administration of NSAIDs may increase the risk of reduced kidney function and could also lead to a decrease in the expected blood pressure-lowering effect.


Q: Does Amlotens affect sleep or cause insomnia?

A: Official product information lists insomnia (difficulty sleeping) as an uncommon adverse event associated with the use of Amlotens. Conversely, some studies also report feelings of extreme drowsiness or sleepiness. Changes in sleep patterns are events that may be reported to a healthcare provider.


Q: Can Amlotens be taken if a person has heart failure?

A: Official regulatory documents state that Amlotens is contraindicated in cases of haemodynamically unstable heart failure that occurs after a heart attack. For other types of heart failure, the product information notes that the use of the drug requires caution. However, one clinical study conducted in patients with severe heart failure did not show an increased risk of mortality or combined morbidity/mortality.


Q: Why do official sources state Amlotens helps control blood pressure but not cure it?

A: According to official drug information, Amlotens is used to help control chronic conditions such as high blood pressure and angina. Official sources specify that the medicine manages the symptoms and underlying disease process but does not provide a cure for these conditions.


Q: Can lifestyle changes still help blood pressure even while taking Amlotens?

A: Regulatory documents describe the control of high blood pressure as one part of a comprehensive cardiovascular risk management approach. This broad approach includes other factors cited in official sources, such as managing cholesterol and diabetes, stopping smoking, regular exercise, and limiting sodium intake.


Q: Is Amlotens known to cause a dry mouth?

A: Official product information indicates that dry mouth is an effect reported in postmarketing surveillance data for Amlotens. This means the event has been documented by users outside of initial clinical trials.


Q: Does Amlotens have a known potential to interact with herbal supplements?

A: The official medicine information specifically mentions a potential interaction with the herbal supplement St John's wort. The use of this or any other herbal supplement is a matter that may be reviewed by a healthcare provider.


Q: Is Amlotens linked to any changes in sexual function?

A: Official product information notes that sexual dysfunction has been reported in postmarketing data for both male and female patients taking Amlotens. This event is documented as part of the drug's overall safety profile.


Q: Can Amlotens be taken if a person has a history of gastrointestinal problems?

A: According to official sources, adverse events in the gastrointestinal system, such as constipation, diarrhea, abdominal pain, and nausea, have been reported in clinical trials related to the use of Amlotens.


Q: Why is it important to keep monitoring blood pressure even after starting Amlotens?

A: Official drug information emphasizes that blood pressure should be checked regularly after starting Amlotens. This regular monitoring helps determine the individual's response to the medicine and is a standard procedure to assess the ongoing response to the medication.


Q: What is the definition of a 'contraindication' for a medicine like Amlotens?

A: A contraindication is a medical term used in official regulatory documents to refer to a circumstance where the medicine is not recommended for use. Examples of contraindications for Amlotens include a known allergy to the active ingredient or having very low blood pressure.


Q: Does Amlotens cause any issues with potassium levels in the body?

A: The single-ingredient form of Amlotens does not typically cause issues with potassium. However, when Amlodipine is used in a combination product with an Angiotensin II Receptor Blocker (a different type of blood pressure medicine), regulatory warnings note that potassium levels are typically monitored in susceptible patients due to the potential risk of elevated potassium, known as hyperkalemia.


Q: What are the official recommendations regarding driving or operating machinery while on Amlotens?

A: Official regulatory information advises caution regarding activities like driving or operating machinery. If Amlotens is associated with effects such as dizziness or feelings of sleepiness, operating machinery or driving is not recommended until these feelings have passed.

How should Amlotens be stored and disposed of?

How to Store and Dispose of Amlotens

Properly storing Amlotens (amlodipine) is essential to maintain its efficacy and safety. The storage requirements differ based on the form:

  • Amlodipine Tablets should be stored at controlled room temperature, typically between 68°F and 77°F (20°C and 25°C). Keep the tablets in the container they came in, tightly closed, and protected from excess heat, moisture, and direct sunlight.

  • Amlodipine Oral Suspension requires refrigeration and must not be frozen. It should also be protected from light.

Safety and Disposal:

Keep all forms of this medication out of the sight and reach of children. Use safety caps and ensure containers are tightly locked. Specific disposal instructions for unused medication should follow local guidelines. Do not flush medications down the toilet unless the manufacturer's labeling specifically instructs you to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlotens found in:

A-Z Index: